Raymond James analyst Andrew Cooper upgraded Myriad Genetics to Outperform from Market Perform with a $25 price target. 2023 should represent a year of solidifying the new trajectory after several choppy/disrupted/somewhat opaque periods, Cooper tells investors in a research note. The improved visibility into a base that has some attractive components, combined with improving execution and a pipeline of assets that should prove additive over time, make for a more compelling investment at current levels, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics upgraded to Outperform from Market Perform at Raymond James
- Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
- Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
- Myriad Genetics appoints Glenn Farrell as CMO
- Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans